NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.880
+0.020 (1.08%)
At close: Jul 10, 2026, 4:00 PM EDT
1.926
+0.046 (2.43%)
After-hours: Jul 10, 2026, 7:54 PM EDT
NervGen Pharma Earnings Call Transcripts
Fiscal Year 2026
-
NVG-291, a peptide therapy for chronic cervical spinal cord injury, showed significant functional and quality-of-life improvements in the CONNECT trial, with a strong safety profile. The upcoming RESTORE phase III trial is designed for regulatory approval, targeting a large unmet need and leveraging a cost-efficient, scalable approach.